"Political directives should not prevent individuals from seeking safe and effective care that they desire and deserve," ...

Stem cell transplants could produce promising remission rates for children with severe monogenic inflammatory bowel disease ...

Danny Rischin, MD, medical oncologist, clinician researcher, Peter McCallum Cancer Centre, discusses a novel adjuvant ...

US workers facing high economic hardship, especially those in lower-wage occupations, were significantly more likely to ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

Panelists discuss how to overcome barriers to comprehensive molecular testing and how to prioritize treatment when ALK+ ...

Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; ...

Developments in artificial intelligence (AI) can help clinicians to diagnose thoracic conditions that may be miss on first glance.

Dirk Arnold, MD, PhD, medical director, Asklepios Tumour Biology Centre, discusses a phase 3 clinical trial investigating amivantamab in metastatic colorectal cancer.

Lenacapavir works to both treat and prevent HIV, making it a promising drug should it be approved by the FDA later this month.

Jill Feldman, cofounder and president, EGFR Resisters, shares the importance of being proactive in managing dermatologic toxicities in epidermal growth factor receptor (EGFR)–positive lung cancer.

The value of the combination of albuterol/budesonide is high due to its alleviating of corticosteroid burden, according to Reynold Panettieri Jr, MD.